Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets

Out-
      side
 

How AI will impact MRI :
only diagnostics 
saving time 
reducing cost 
makes planning obsolete 
reduce human knowledge 
not at all 


 
MRI Contrast Agents
• Classifications, Characteristics, etc. •
• Contrast Agents For Intravenous Use / Magnetic Characteristics
• Contrast Agents For Intravenous Use / Pharmacokinetics
• Contrast Agents For Intravenous Use / Distribution
• Contrast Agents For Oral Use / Magnetic Characteristics
• Contrast Agents For Oral Use / Signal Characteristics
  
Radiology Contrast Agents Open this link in a new window Ultrasound Imaging Contrast Agents Open this link in a new window
Contrast Agents For Intravenous Use / Pharmacokinetics
Ionic Intravenous Contrast Agents  
Intravenous contrast agents used in MRI are distributed in the extracellular spaces of the body before being excreted. In this sense they are similar to iodinated X-ray contrast media. However, contrast agents used for MRI are quite different from conventional radiographic contrast media in structure and function and there is no known cross sensitivity between these types of contrast agents. Common MRI contrast agents use metal ions (e.g., gadolinium or manganese) complexed with organic molecules.
Gd-DTPA, an ionic linear molecule complex (gadopentetate dimeglumine) was the first marketed MRI contrast agent. Although the osmolality of this substances can be relatively high (up to 1940 mOsm/kg H2O) compared with plasma, adverse reactions and side effects are very rare. The used doses are smaller compared with radiographic contrast media.

See also Nonionic Intravenous Contrast Agents, Dotarem®, and Magnevist®.
 
Images, Movies, Sliders:
 Breast MRI Images T1 Pre - Post Contrast  Open this link in a new window
      
 

• View the DATABASE results for 'Ionic Intravenous Contrast Agents' (5).Open this link in a new window

 
Further Reading:
MR-TIP Forum - Related Threads 
• 'MRI contrast agents'
• 'Omniscan Distribution Rate'
• 'CE-MRA Vasovist protocol'
• 'Endorem Resovist'
• '???'

Nonionic Intravenous Contrast Agents  
Radiographic low-osmolar nonionic contrast agents have less side effects and fewer nephrotoxicity than ionic, high-osmolar agents. Gadolinium-based MRI contrast agents have a different formulation from iodinated X-ray contrast media, and there is no known cross sensitivity between these two types of contrast agents. Intravenous MRI contrast agents, specifically the gadolinium chelates have a high safety and lack of nephrotoxicity compared with X-ray contrast media.
The used gadolinium chelates differ in following properties: linear (e.g., gadodiamide and gadoversetamide have nonionic linear structures) vs. macrocyclic cores, and ionic vs. nonionic types. The nonionic molecules have lower osmolality and viscosity, which increase digestibility at greater concentrations, and make faster bolus injections conceivable. The macrocyclic molecules (e.g., gadoteridol has a nonionic macrocyclic ring structure) are more stable and show fewer tendencies to dissociate free Gd.

See also ProHance®, Omniscan®, OptiMARK®, Ionic Intravenous Contrast Agents.

See also the related poll result: 'MRI will have replaced 50% of x-ray exams by'

• View the DATABASE results for 'Nonionic Intravenous Contrast Agents' (4).Open this link in a new window

 
MRI Knowledge Resources from Universities, Companies, Agencies, etc. 
• Software
• Mobile MRI
• Functional MRI
• Image Quality
• Contrast Agents

  Contrast Agents For Intravenous Use / Distribution top
Radiology Contrast Agents Open this link in a new window Ultrasound Imaging Contrast Agents Open this link in a new window
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?    



Look
      Ups




MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • Medical-Ultrasound-Imaging • 
Copyright © 2003 - 2024 SoftWays. All rights reserved. [ 28 March 2024]
Terms of Use | Privacy Policy | Advertising
 [last update: 2024-02-26 03:41:00]